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Abstract
Background: Diffuse large B-cell lymphoma (DLBCL) comprises 31% of lymphomas in the United States. Although
it is an aggressive type of lymphoma, 40% to 50% of patients are cured with treatment. The study objectives were
to identify patient factors associated with treatment and survival in DLBCL.
Methods: Using Surveillance, Epidemiology, and End Results (SEER) registry data linked to Medicare claims, we
identified 7,048 patients diagnosed with DLBCL between January 1, 2001 and December 31, 2005. Patients were
followed from diagnosis until the end of their claims history (maximum December 31, 2007) or death. Medicare
claims were used to characterize the first infused chemo-immunotherapy (C-I therapy) regimen and to identify
radiation. Multivariate analyses were performed to identify patient demographic, socioeconomic, and clinical factors
associated with treatment and with survival. Outcomes variables in the survival analysis were all-cause mortality,
non-Hodgkin’s lymphoma (NHL) mortality, and other/unknown cause mortality.
Results: Overall, 84% (n = 5,887) received C-I therapy or radiation treatment during the observation period: both,
26%; C-I therapy alone, 53%; and radiation alone, 5%. Median age at diagnosis was 77 years, 54% were female, 88%
were white, and 43% had Stage III or IV disease at diagnosis. The median time to first treatment was 42 days, and
92% of these patients had received their first treatment by day 180 following diagnosis. In multivariate analysis, the
treatment rate was significantly lower among patients ≥ 80 years old, blacks versus whites, those living in a census
tract with ≥ 12% poverty, and extra-nodal disease. Blacks had a lower treatment rate overall (Hazard Ratio [HR] 0.77;
P < 0.001), and were less likely to receive treatment within 180 days of diagnosis (Odds Ratio [OR] 0.63; P = 0.002)
than whites. In multivariate survival analysis, black race was associated with higher all-cause mortality (HR 1.24; P =
0.01) and other/unknown cause mortality (HR 1.35; P = 0.01), but not mortality due to NHL (HR 1.16; P = 0.19).
Conclusions: In elderly patients diagnosed with DLBCL, there are large differences in treatment access and survival
between blacks and whites.
Background
DLBCL is the most common type of NHL, with an esti-
mated 20,300 new cases in the United States in 2010
[1-3]. It is classified as an aggressive form of NHL [3]
because survival is limited in the absence of effective
treatment [4]. There have been substantial changes in
the treatment of DLBCL in the past two decades. For
instance, prior to the introduction of the monoclonal
antibody rituximab (Genentech, South San Francisco,
CA), the mainstay of treatment for DLBCL was CHOP
(cyclophosphamide, doxorubicin, vincristine, and predni-
sone), with a three year overall survival of approximately
54% [5]. In 2002, a landmark study by Coiffier et al.
demonstrated that rituximab plus CHOP (R-CHOP) sig-
nificantly improved overall survival compared to CHOP
alone in elderly patients with DLBCL [6]. Based on this
study, and later studies that confirmed the findings
[7-10], R-CHOP is now recommended as frontline ther-
apy for most patients with advanced (Ann Arbor Stage
III-IV) disease and many with localized (Ann Arbor
stage I-II) disease [3]. * Correspondence: bob@outins.com
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any medium, provided the original work is properly cited.The existence of racial and ethnic disparities in health
care access and outcomes is well-documented. An Insti-
tute of Medicine report [11] found that even when
access-related factors such as insurance status and the
ability to pay for care are the same, African Americans
and Hispanics tend to receive a lower quality of health
care across a range of disease areas and clinical services,
including cancer. According to the American Cancer
Society, African Americans are more likely to develop
and die from cancer than any other racial or ethnic
group [1]. Not surprisingly, therefore, considerable
attention has been focused on better understanding
racial and ethnic disparities in cancer care and out-
comes, including NHL [12-14].
One recent study by Wang and colleagues examined
ethnic variations in treatment and survival in patients
diagnosed with NHL, including DLBCL and two indo-
lent types of NHL: chronic lymphocytic leukemia (CLL);
and follicular lymphoma (FL) [14]. This was a retrospec-
tive cohort study of patients diagnosed with NHL from
1992 to 1999, using the SEER-Medicare linked database.
Based on multivariate analysis, the investigators found
that among all patients diagnosed with NHL, blacks
were significantly less likely than whites to receive che-
motherapy (OR, 0.69; 95% confidence interval [CI],
0.50-0.95). The study found no difference in all-cause
mortality between blacks and whites, either overall or in
any of the specific types of NHL, including DLBCL.
Several changes in the treatment of NHL have
occurred since the patients included in this study were
diagnosed, including the introduction of rituximab,
updated clinical practice guidelines, and ongoing pres-
sures on the health system to reduce costs while
improving outcomes. These may have impacted racial
and ethnic disparities in access and outcomes in NHL,
and in particular aggressive types such as DLBCL. For
instance, the impact of racial and ethnic disparities in
access to treatment for DLBCL, as documented by
Wang and colleagues [14], could increase disparities in
outcomes such as survival in the presence of more effec-
tive treatments such as R-CHOP. Therefore, the purpose
of the present study was to identify factors associated
with treatment and survival in a cohort of patients diag-
nosed with DLBCL during the period when rituximab
was introduced, with a particular focus on race/
ethnicity.
Methods
Data Source
The source of data for this study was the National Can-
cer Institute’s (NCI) SEER cancer registry linked to
Medicare enrollment and claims data. This database has
been described in detail elsewhere [15]. Briefly, as of
2010, SEER collects and publishes cancer incidence and
survival data from 18 population-based cancer registries
throughout the United States covering approximately
26% of the US population [16]. SEER coverage includes
23% of African Americans, 40% of Hispanics, 42% of
American Indians and Alaska Natives, 53% of Asians,
and 70% of Hawaiian/Pacific Islanders.
The registries routinely collect data on patient demo-
graphics, primary tumor site, tumor morphology and
stage at diagnosis, first course of treatment, and follow-
up for vital status. In the SEER-Medicare data, cancer
registry data are linked to Medicare enrollment and
claims data. For persons age 65 years or older, 97% are
eligible for Medicare, and 93% of patients in the SEER
files are matched to the Medicare enrollment file [17].
Almost all Medicare beneficiaries have Part A coverage,
which includes hospital, skilled nursing facility, hospice,
and some home health care, and 96% of Part A benefici-
aries choose to enroll in Part B of Medicare, which cov-
ers physician and outpatient services. At the time this
study was performed, the SEER-Medicare linkage
included all Medicare-eligible persons appearing in the
SEER data through 2005 and their Medicare claims
through 2007.
Patient Eligibility
Patients were included in this study if they were diag-
nosed with DLBCL between January 1, 2001 and
December 31, 2005, and DLBCL was the first primary
cancer diagnosed. Identification of DLBCL was made
using two World Health Organization (WHO) Interna-
tional Classification of Diseases for Oncology, 3
rd Edi-
tion (ICD-O-3) histology codes: 9680 (malignant
lymphoma, large B-cell, diffuse, centroblastic, NOS) and
9684 (malignant lymphoma, large B-cell, diffuse, immu-
noblastic, NOS) [18,19]. Patients were excluded for the
following reasons: DLBCL diagnosed before age 65;
diagnosis made by death certificate or autopsy; death
within the first month following diagnosis; or Medicare
enrollment less than 12 months before diagnosis. In
addition, to ensure complete claims history, patients had
to have been enrolled in both Medicare Parts A and B,
with no health maintenance organization (HMO) cover-
age for 12 months prior to diagnosis. SEER reports date
of diagnosis as month and year only. In this study, the
first day of the SEER month of diagnosis was assigned
as the day of diagnosis. After diagnosis, patients were
followed until death, enrollment in an HMO, develop-
ment of a second primary tumor, or the last date for
which Medicare claims were available.
Treatments
Medicare claims were used to identify the time of
the first infused C-I therapy and radiation treatments
provided to patients after diagnosis. International
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th Revision, Clinical Modifi-
cation (ICD-9-CM) procedurec o d e s[ 2 0 ] ,a n dH e a l t h -
care Common Procedure Coding System (HCPCS)
codes [21], and revenue codes were used to identify C-I
and radiation therapy from both inpatient and outpati-
ent claims. A list of codes is included in the Appendix.
The first C-I therapy regimen was reconstructed from
30 days of claims after the first C-I therapy infusion.
Patients were classified as taking either CHOP or CVP
(cyclophosphamide, vincristine, and prednisone) by
assuming the use of prednisone when the other agents
were present, because oral medications with no intrave-
nous equivalent were not available in SEER-Medicare at
the time our study was conducted. The use of rituximab
with these was classified as R-CHOP or R-CVP. If other
chemotherapy agents were used, or patients had claims
indicative of chemotherapy infusions without the
HCPCS codes (i.e., J-codes) to identify the specific che-
motherapy agents, these were classified as “other” with
or without rituximab.
Mortality and Censoring
T h ed a t eo fd e a t hw a sa s s i g n e db yu s i n gt h eM e d i c a r e
date, if available, even in cases where the SEER date was
also available. The Medicare date was preferred because
it is more current than the SEER date [22]. In cases
where the SEER date of death was available but missing
for Medicare, the SEER date was used. The cause of
death was classified as NHL or other/unknown cause
based on ICD-9-CM codes. All other patients were
assumed to be alive at the end of the analysis period
(December 31, 2007), although they may have been cen-
sored earlier for other reasons, such as switching to
HMO coverage.
Patient Characteristics
Patients were described according to their demographic,
clinical, and socioeconomic characteristics. Patient age
at diagnosis was stratified into four groups: 66 - 69; 70 -
74; 75 - 79; and ≥ 80. Requiring eligible patients to have
at least one year of Medicare enrollment prior to diag-
nosis ensured that the minimum age in the cohort was
66 years. Race/ethnicity was defined using the SEER re-
coded race variable in combination with the Medicare
race variable as follows: black, if both variables indicated
black race; white, if both variables indicated white race,
or if the Medicare variable indicated white race and the
SEER variable indicated Hispanic ethnicity (since SEER
uses Hispanic surname to assign Hispanic ethnicity);
and other, which in SEER consists predominantly of
American Indian/Native Alaskan, Native Hawaiian or
Other Pacific Islander, and Asian [23].
Summary staging is the approach SEER uses to cate-
gorize how far a cancer has spread from its point of
origin [24]. It uses all information available in the medi-
cal record, and is a combination of the most precise
clinical and pathological documentation of the extent of
disease. DLBCL is classified as Stage I-IV according to
the number of lymph node regions, the location of
those regions, involvement of the spleen, and involve-
ment of extra-lymphatic organs/sites. With the excep-
tion of Stage IV disease, in which all patients have
multifocal involvement, patients classified as Stage I-III
may or may not have extra-nodal involvement. Conse-
quently, patients also were classified according to
whether their disease was confined to one or more
lymph node regions (nodal), or involved the spleen or
an extra-lymphatic organ or site (extra-nodal). Finally,
they were classified according to the histologic subtype
of DLBCL: centroblastic (ICD-O-3 code 9680); or
immunoblastic (ICD-O-3 code 9684) [18,19].
We used the Medicare inpatient (Part A), outpatient,
and physician (Part B) records to calculate an NCI
Comorbidity Index score for each patient [25]. This
approach [26,27] entails first removing claims that are
considered to have unreliable diagnosis coding, such as
those for testing procedures used to rule out conditions.
Then, remaining diagnosis and procedure codes are
used to identify the 15 non-cancer comorbidities in the
Charlson Comorbidity Index (CCI) [28]. The algorithms
used to identify these conditions reflect the Deyo [29]
adaptation of the CCI, and include several procedure
codes from the Romano [30] adaptation. A weight is
assigned to each condition, and the weights are summed
to obtain the index for each patient. Medicare inpatient
and outpatient claims, excluding those likely to be made
only for testing purposes, were used to identify the pre-
sence of anemia, neutropenia, thrombocytopenia, and
other cardiovascular disease prior to diagnosis. These
are not included in the NCI Comorbidity Index.
Socioeconomic information at the patient level is not
available through SEER-Medicare. Instead, the SEER-
Medicare dataset contains information from the 2000
Census, reported at the tract level in which the patient
lives, for the percent of the population living in poverty
and the percent of those age 25 years or older with
some college. We used these as indicators of the socioe-
conomic status of individual patients in the DLBCL
cohort. SEER registry (consolidated into 13 regions, with
California as a single region, and excluding Arizona
Native Americans) and the assigned metropolitan statis-
tical area as recoded by SEER (big metropolitan, metro-
politan, urban, less urban, and rural) were used as
geographic indicators.
Statistical Analysis
Cox proportional hazards regression was used to iden-
tify factors associated with treatment and survival.
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stratified by Stage I-II versus III-IV at diagnosis. In addi-
tion to time-to-treatment analyses, logistic regression
was used to identify factors associated with receiving
therapy within 180 days following diagnosis. Survival
analysis was conducted with three different mortality
endpoints: all-cause mortality; NHL mortality; and
other/unknown cause mortality. The base case multi-
variate survival analyses were performed without treat-
ment as a covariate, such that any racial disparities in
access to treatment that also impacted survival were
captured in the race covariates in the survival analyses.
We then repeated all the multivariate survival analyses
with treatment included as a time dependent covariate.
We reasoned that comparing the race covariates from
models with versus without treatment included would
provide insight into the impact racial disparities in
access to treatment had on racial disparities in survival.
Editorial Note
Notification of all NCI approvals for this study was
obtained from IMS, Inc., via email correspondence, on
July 29th, 2008. At the time this study was approved,
NCI did not require Institutional Review Board approval
prior to releasing SEER-Medicare data. However, since
the SEER-Medicare data contain information about geo-
graphic location at the county level, as well as dates of
receiving health care services, the SEER-Medicare data
are considered by Health Insurance Portability and
Accountability Act (HIPAA) requirements as a limited
data set, which requires that all investigators sign a Data
Use Agreement (DUA) prior to receiving the data. The
DUA for this study was executed by Dr. Danese on June
7, 2008.
Results
We identified 7,048 patients who met the study eligibil-
ity criteria (Table 1). The median age at diagnosis was
77 years, 54% were female, 88% were white, and 43%
had Stage III or IV disease at diagnosis. Overall, 5,887
(84%) received C-I therapy or radiation treatment during
the observation period: 5,555 (94%) received C-I therapy
with (1,826: 31%) or without radiation (3,729: 63%); and
the remainder (332: 6%) received radiation alone (not
shown in Table). Among those who received C-I ther-
apy (5,555), 46% (2,569) received chemotherapy alone,
45% (2,488) received rituximab plus chemotherapy, and
the remainder (498:9%) received rituximab alone.
R-CHOP was the most common chemotherapy regimen
(2,167: 39%).
As shown in Figure 1, the median time to first treat-
ment following DLBCL diagnosis was 42 days, and 92%
(5,398/5,887) of the patients receiving treatment began
within 180 days following diagnosis. The unadjusted
time to beginning treatment was 10 days longer for
blacks versus whites. In multivariate analysis of time to
treatment using Cox regression, the treatment rate was
significantly lower among patients ≥ 80 years old, blacks
versus whites, those living in a census tract with ≥ 12%
poverty, and extra-nodal disease. The treatment rate
was higher in those diagnosed with later-stage disease
(Table 2). In stratified analyses, the treatment rate was
l o w e ri nb l a c k st h a nw h i t e sa m o n gS t a g eI - I Ia n d
among Stage III-IV patients. Findings from the logistic
regression analysis of treatment within the first 180 days
following treatment were consistent with those from the
Cox regression analyses (Table 2), except that generally
the effect sizes were larger in the logistic regression ana-
lysis. For instance, in the logistic regression model, the
OR for treatment among blacks versus whites was 0.63
compared to a HR of 0.77 in the Cox model that
included all patients.
T h e r ew e r e4 , 1 8 8( 5 9 %o ft h ep o p u l a t i o n )d e a t h sd u r -
ing the observation period: 2,366 (56%) had NHL listed
as the cause of death, and the remaining 1,822 (44%) had
another cause listed (919: 50%) or the cause of death was
not recorded (903: 50%). The median survival was two
years, and 95% survived at least six weeks following diag-
nosis, which, as reported above, was also the median time
to initial treatment. In multivariate survival analysis using
Cox regression, which did not include treatment as a
covariate, older age, male gender, black race, immuno-
blastic histology, advanced stage at diagnosis, higher NCI
Comorbidity Index, anemia, cardiovascular disease, and
living in a census area with ≥ 12% poverty all were asso-
ciated with higher all-cause mortality (Table 3). Being
diagnosed later in the observation period was associated
with lower all-cause mortality. Black race was associated
with higher mortality due to other/unknown causes but
it was not associated with higher mortality due to NHL.
In the NHL mortality model, the effect sizes were larger
for histology, Stage, year of diagnosis, and anemia than in
the other/unknown cause mortality model. In the other/
unknown cause mortality model, effect sizes were larger
for age, NCI Comorbidity Index, cardiovascular disease,
and poverty.
In multivariate analyses stratified by Stage I-II and III-
IV (Table 4), which did not include treatment as a cov-
ariate, black race was associated with significantly higher
all-cause mortality among Stage III-IV patients, but not
among Stage I-II patients. The effect sizes for age, gen-
der, NCI Comorbidity Index, and cardiovascular disease
were larger in the model of Stage I-II patients than the
model of Stage III-IV patients, whereas the effect size
f o ry e a ro fd i a g n o s i sw a sl a r g e ri nt h em o d e lo fS t a g e
III-IV patients.
In multivariate survival analyses that did include treat-
ment (Yes/No) as a covariate, the associations between
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Overall
Freq
% Treatment
Freq
% No Treatment
Freq
% P Value
Total 7,048 100 5,887 83.5 1,161 16.5
Age
66-69 985 14.0 889 15.1 96 8.3
70-74 1,576 22.4 1,384 23.5 192 16.5 <0.0001
75-79 1,742 24.7 1,497 25.4 245 21.1
≥ 80 2,745 38.9 2,117 36.0 628 54.1
Median Age 77 72-82 77 72-82 80 75-86
Gender
Male 3,228 45.8 2,685 45.6 543 46.8 <0.01
Female 3,820 54.2 3,202 54.4 618 53.2
Race
Black 240 3.4 171 2.9 59 5.1
Other 632 9.0 489 8.3 110 9.5 0.01
White 6,176 87.6 5,184 88.1 992 85.4
Stage at diagnosis
I 2,182 31.0 1,838 31.2 344 29.6
II 1,330 18.9 1,158 19.7 172 14.8
III 1,009 14.3 866 14.7 143 12.3 <0.0001
IV 2,044 28.4 1,661 28.2 383 33.0
unknown 483 6.9 364 6.2 119 10.2
Histology 0.0
Centroblastic 6,902 97.9 5,773 98.1 1,129 97.2 0.07
Immunoblastic 146 2.1 114 1.9 32 2.8
Lymph node site
Extranodal 4,218 59.8 3,486 59.2 732 63.0 <0.0001
Nodal 2,347 33.3 2,037 34.6 310 26.7
Unkown 483 6.9 364 6.2 119 10.2
NCI Comorbidity Index
0 4,075 57.8 3,458 58.7 617 53.1 <0.0001
1 1,729 24.5 1,453 24.7 276 23.8
2 707 10.0 579 9.8 128 11.0
≥ 3 537 7.6 397 6.7 140 12.1
Year of diagnosis
2001 1,300 18.4 1,065 18.1 235 20.2
2002 1,395 19.8 1,160 19.7 235 20.2 <0.01
2003 1,445 20.5 1,237 21.0 208 17.9
2004 1,465 20.8 1,230 20.9 235 20.2
2005 1,443 20.5 1,195 20.3 248 21.4
SEER region
CT 435 6.2 365 6.2 70 6.0
Detroit 482 6.8 409 6.9 73 6.3
HI 84 1.2 70 1.2 14 1.2
IA 526 7.5 453 7.7 73 6.3
NM 166 2.4 133 2.3 33 2.8
Seattle 397 5.6 331 5.6 66 5.7 <0.01
UT 253 3.6 206 3.5 47 4.0
Atlanta 184 2.6 NS NS NS NS
Rural GA 20 0.3 NS NS NS NS
KY 614 8.7 496 8.4 118 10.2
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LA 506 7.2 419 7.1 87 7.5
NJ 1,223 17.4 1,045 17.8 178 15.3
CA 2,158 30.6 1,788 30.4 370 31.9
Percent of 25+ year olds in
census tract with some college
0.87
0-<25% 2,535 36.0 2,127 36.1 408 35.1
≥25% 4,513 64.0 3,760 63.9 753 64.9
Urban vs.rural
Big Metro 3,867 54.9 3,256 55.3 611 52.6
Metro 2,071 29.4 1,708 29.0 363 31.3 0.33
Urban 410 5.8 342 5.8 68 5.9
Less Urban 570 8.1 470 8.0 100 8.6
Rural 130 1.8 111 1.9 19 1.6
Percent living in poverty
in census tract
Missing 38 0.5 NS NS NS NS
0-<5% 2,311 32.8 NS NS NS NS 0.05
5-<7% 978 13.9 811 13.8 167 14.4
7-<12% 1,552 22.0 1306 22.2 246 21.2
≥12% 2,169 30.8 1762 29.9 407 35.1
Other conditions
Anemia 652 9.3 501 8.5 151 13.0 <0.0001
Neutropenia 14 0.2 NS NS NS NS 0.65
Thrombocytopenia 43 0.6 NS NS NS NS 0.52
Cardiovascular disease 849 12.0 659 11.2 190 16.4 <0.0001
Treatment consisted of chemo-immunotherapy, radiation therapy, or both
NS: Not shown due to at least one cell in the characteristic with < 11 observations
Figure 1 Time to Treatment, by Race.
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Time to Treatment -
Overall
Time to Treatment -
Stage I & II
Time to Treatment -
Stage III & IV
Treatment within 180
days
HR p-
value
95% CI HR p-
value
95% CI HR p-
value
95% CI OR p-
value
95% CI
Age
64-< 70 ref.
70-< 75 1.00 0.91 0.91 1.08 0.90 0.07 0.79 1.01 1.10 0.16 0.96 1.24 0.73 0.01 0.59 0.91
75-< 80 0.95 0.20 0.87 1.03 0.91 0.12 0.81 1.03 0.99 0.86 0.87 1.12 0.59 <
0.0001
0.48 0.73
≥ 80 0.78 <
0.0001
0.72 0.84 0.69 <
0.0001
0.62 0.77 0.89 0.07 0.79 1.01 0.38 <
0.0001
0.31 0.46
Gender
Female ref.
Male 0.99 0.70 0.94 1.04 1.01 0.83 0.94 1.09 0.97 0.42 0.89 1.05 0.85 0.01 0.76 0.95
Race
White ref
Black 0.77 <
0.001
0.66 0.89 0.76 0.01 0.61 0.95 0.76 0.02 0.60 0.96 0.63 < 0.01 0.47 0.85
other 1.01 0.78 0.92 1.12 1.06 0.42 0.92 1.21 0.95 0.57 0.81 1.12 0.99 0.89 0.79 1.22
Histology
9680 ref
9684 0.86 0.10 0.71 1.03 0.70 0.01 0.53 0.92 1.16 0.27 0.89 1.50 0.66 0.03 0.45 0.95
Stage at diagnosis
I ref
II 1.20 <
0.0001
1.11 1.29 1.21 <
0.0001
1.12 1.30 1.32 < 0.01 1.11 1.58
III 1.27 <
0.0001
1.17 1.38 1.04 0.71 0.86 1.26
IV 1.23 <
0.0001
1.14 1.32 0.93 0.37 0.80 1.08 0.91 0.22 0.78 1.06
unknown 0.85 0.01 0.75 0.96 0.56 <
0.0001
0.44 0.71
NCI Comorbidity Index
0 ref
1 1.05 0.15 0.98 1.12 1.03 0.53 0.94 1.13 1.09 0.07 0.99 1.20 1.00 0.95 0.86 1.15
2 1.03 0.51 0.94 1.14 1.03 0.64 0.90 1.18 1.09 0.24 0.94 1.26 0.87 0.19 0.71 1.07
≥3 0.93 0.25 0.82 1.05 1.04 0.64 0.88 1.24 0.89 0.25 0.73 1.09 0.56 <
0.0001
0.44 0.71
Year of diagnosis
2001 ref
2002 0.99 0.84 0.91 1.08 0.95 0.35 0.84 1.06 1.08 0.25 0.95 1.23 0.95 0.57 0.79 1.14
2003 1.04 0.37 0.96 1.13 1.00 0.99 0.89 1.12 1.10 0.14 0.97 1.25 1.18 0.08 0.98 1.42
2004 1.03 0.53 0.95 1.12 1.00 0.98 0.89 1.12 1.04 0.51 0.92 1.19 1.17 0.09 0.98 1.41
2005 0.99 0.89 0.91 1.08 0.93 0.26 0.83 1.05 1.08 0.24 0.95 1.22 1.00 0.99 0.83 1.20
Percent of 25+ year
olds in census tract
with some college
0-< 25% ref
25-< 50% 0.95 0.11 0.89 1.01 0.91 0.03 0.83 0.99 0.96 0.39 0.87 1.06 0.92 0.25 0.80 1.06
≥50% 0.84 0.34 0.59 1.20 0.87 0.61 0.52 1.46 0.87 0.68 0.45 1.70 0.50 0.04 0.26 0.98
Percent living in
poverty in census tract
0-< 5% ref
5-< 7% 0.92 0.04 0.84 1.00 0.94 0.31 0.84 1.06 0.92 0.18 0.81 1.04 0.87 0.15 0.73 1.05
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race and other/unknown cause mortality, remained sta-
tistically significant (HR = 1.19, P = 0.04; and HR 1.27,
P = 0.05, respectively). In the multivariate analyses stra-
tified by Stage, black race remained significant for
patients diagnosed with Stage III-IV disease (HR = 1.28,
P = 0.03). Treatment was statistically significant in all
five models.
Discussion
We conducted a study using SEER-Medicare to identify
factors associated with treatment and mortality in an
elderly cohort of patients diagnosed with DLBCL. In
particular, we sought to understand whether racial dif-
ferences in treatment observed in an earlier study of
SEER-Medicare data [14] were present in more recent
SEER-Medicare data. Also, we reasoned that any
observed differences in treatment might now translate
into greater differences in survival following the intro-
duction of rituximab, which, when added to CHOP, has
been shown to improve overall survival in aggressive
NHL [6-10]. Our findings show that blacks were less
likely to receive treatment than whites. In multivariate
analysis of time to initial treatment, the adjusted rate of
treatment was 23% lower in blacks than whites. Further-
more, blacks were 37% less likely than whites to begin
treatment within the first 180 days following diagnosis.
The difference between the black race coefficients in
these two models, as well as the Kaplan-Meier curves
illustrating time to first treatment, suggest that while
there were persistent differences in treatment rates dur-
ing the entire observation period, the differences were
greatest within the first six months following diagnosis.
This is of considerable concern in DLBCL since it is an
aggressive type of NHL where frontline treatment with
C-I therapy is now recommended in most instances [3].
We next examined factors associated with mortality.
In the multivariate survival analysis, black race was asso-
ciated with 24% higher all-cause mortality, adjusting for
demographic and clinical covariables. When we divided
the cause of death into that recorded as NHL versus
other/unknown, we found that black race was associated
with 35% higher mortality due to other/unknown causes.
However, black race was not associated with statistically
significantly higher NHL mortality. When we compared
these two models, we found that several of the cancer
Table 2 Multivariate Analysis of Treatment (Continued)
7-< 12% 0.97 0.36 0.90 1.04 0.95 0.32 0.86 1.05 0.97 0.54 0.86 1.08 0.95 0.51 0.80 1.12
≥12% 0.90 0.01 0.83 0.97 0.92 0.10 0.82 1.02 0.89 0.04 0.79 1.00 0.82 0.02 0.70 0.97
SEER region
CA ref
CT 1.05 0.40 0.93 1.19 1.01 0.87 0.86 1.20 1.10 0.33 0.91 1.32 1.14 0.34 0.87 1.50
Detroit 0.99 0.84 0.89 1.10 0.96 0.57 0.82 1.12 1.09 0.32 0.92 1.28 1.07 0.61 0.83 1.37
HI 0.95 0.65 0.74 1.21 0.90 0.54 0.65 1.25 1.01 0.95 0.68 1.50 1.07 0.81 0.62 1.85
IA 1.16 0.01 1.05 1.29 1.31 <
0.001
1.13 1.51 1.04 0.67 0.88 1.22 1.44 < 0.01 1.12 1.86
NM 1.17 0.09 0.98 1.39 1.23 0.10 0.96 1.58 1.11 0.47 0.84 1.47 0.92 0.68 0.64 1.35
Seattle 1.01 0.93 0.89 1.13 1.08 0.40 0.91 1.28 0.97 0.72 0.82 1.15 1.29 0.07 0.98 1.70
UT 0.93 0.32 0.80 1.08 0.91 0.34 0.75 1.11 0.99 0.90 0.79 1.24 0.90 0.52 0.65 1.24
Atlanta 1.08 0.38 0.91 1.27 1.05 0.71 0.82 1.35 1.09 0.47 0.86 1.40 1.16 0.45 0.79 1.69
Rural GA 1.04 0.89 0.62 1.73 0.76 0.47 0.36 1.61 1.32 0.54 0.54 3.22 0.84 0.72 0.31 2.27
KY 0.95 0.37 0.86 1.06 1.00 0.95 0.87 1.16 0.96 0.58 0.81 1.13 0.91 0.42 0.73 1.14
LA 1.06 0.33 0.95 1.18 1.01 0.88 0.87 1.18 1.18 0.06 0.99 1.41 1.09 0.51 0.85 1.39
NJ 1.05 0.32 0.96 1.14 1.05 0.48 0.93 1.18 1.05 0.51 0.91 1.20 0.96 0.65 0.79 1.16
Lymph node site
Nodal ref.
Extra-nodal 0.90 < 0.01 0.85 0.97 0.90 < 0.01 0.83 0.96 0.95 0.55 0.81 1.12 0.88 0.09 0.75 1.02
Other conditions
Anemia 1.04 0.42 0.95 1.14 1.04 0.60 0.90 1.19 1.02 0.83 0.88 1.17 0.67 <
0.0001
0.55 0.80
Neutropenia 1.03 0.93 0.56 1.87 0.47 0.19 0.15 1.46 1.51 0.38 0.61 3.75 0.54 0.28 0.18 1.65
Thrombocytopenia 1.35 0.07 0.97 1.88 1.88 0.02 1.12 3.17 0.97 0.88 0.61 1.54 0.51 0.04 0.27 0.97
Cardiovascular
disease
0.99 0.77 0.89 1.09 1.01 0.86 0.88 1.16 0.93 0.33 0.79 1.08 0.93 0.49 0.76 1.14
HR: Hazard Ratio
OR: Odds Ratio
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Page 8 of 14Table 3 Multivariate Survival Analysis
All Cause (4,188
deaths)
NHL (2,366 deaths) Other/Unknown
Cause (1,822 deaths)
HR p-
value
95% CI HR p-
value
95% CI HR p-
value
95% CI
Age
66-< 70 ref.
70-< 75 1.38 <
0.0001
1.22 1.55 1.37 <
0.001
1.16 1.61 1.38 <
0.001
1.15 1.66
75-< 80 1.75 <
0.0001
1.55 1.96 1.75 <
0.0001
1.50 2.05 1.72 <
0.0001
1.44 2.05
≥ 80 2.69 <
0.0001
2.41 3.00 2.60 <
0.0001
2.24 3.01 2.79 <
0.0001
2.36 3.29
Gender
Female ref.
Male 1.09 < 0.01 1.03 1.16 1.05 0.22 0.97 1.14 1.14 0.01 1.04 1.25
Race
White ref.
Black 1.24 0.01 1.06 1.46 1.16 0.19 0.93 1.45 1.35 0.01 1.06 1.71
Other 1.09 0.17 0.97 1.22 1.11 0.19 0.95 1.30 1.06 0.52 0.89 1.26
DLBCL histology
9680 ref.
9684 1.47 <
0.001
1.21 1.79 1.52 <
0.001
1.19 1.94 1.32 0.11 0.94 1.84
Stage at diagnosis
I ref.
II 1.27 <
0.0001
1.16 1.40 1.42 <
0.0001
1.25 1.62 1.15 0.05 1.00 1.31
III 1.51 <
0.0001
1.36 1.68 1.77 <
0.0001
1.53 2.04 1.28 < 0.01 1.10 1.50
IV 1.86 <
0.0001
1.70 2.02 2.43 <
0.0001
2.16 2.74 1.30 <
0.0001
1.14 1.48
unknown 1.56 <
0.0001
1.36 1.79 1.45 <
0.001
1.19 1.77 1.72 <
0.0001
1.42 2.08
NCI Comorbidity Index
0 ref.
1 1.19 <
0.0001
1.10 1.28 1.14 0.01 1.03 1.26 1.27 <
0.0001
1.13 1.42
2 1.44 <
0.0001
1.29 1.60 1.34 <
0.0001
1.16 1.54 1.58 <
0.0001
1.35 1.85
≥3 1.88 <
0.0001
1.66 2.13 1.70 <
0.0001
1.44 2.01 2.16 <
0.0001
1.79 2.60
Year of Diagnosis
2001 ref.
2002 0.87 < 0.01 0.79 0.96 0.87 0.02 0.77 0.98 0.89 0.14 0.76 1.04
2003 0.82 <
0.0001
0.74 0.90 0.76 <
0.0001
0.67 0.85 0.95 0.52 0.81 1.11
2004 0.84 <
0.001
0.76 0.92 0.70 <
0.0001
0.62 0.79 1.16 0.07 0.99 1.35
2005 0.80 <
0.0001
0.73 0.89 0.39 <
0.0001
0.33 0.45 1.90 <
0.0001
1.63 2.20
Percent of 25+ year olds in census tract with
some college
0-< 25% ref.
25-< 50% 1.00 0.91 0.93 1.07 1.01 0.86 0.91 1.11 0.98 0.77 0.88 1.10
≥50% 0.90 0.61 0.60 1.35 0.81 0.46 0.45 1.43 1.00 1.00 0.57 1.76
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Page 9 of 14covariables, e.g. Stage, histology, and anemia, had larger
effects in the NHL mortality model than in the other/
unknown cause mortality model. Also, the effect of year
of diagnosis was greater in the NHL model than in the
other/unknown cause mortality model, perhaps reflect-
ing improvements in treatment of DLBCL over time. In
contrast, several of the demographic and general comor-
bidity variables, e.g. gender, NCI Comorbidity Index,
poverty, and cardiovascular disease, had larger effects in
the other/unknown cause mortality model than the
NHL model. When we stratified the analysis of all-cause
mortality by disease Stage at diagnosis, we found that
black race was associated with 35% higher mortality in
Stage III-IV patients, but not with statistically signifi-
cantly higher mortality in Stage I-II patients. In general,
the cancer covariables had greater effects in the Stage
III-IV model than in the Stage I-II model, and the oppo-
site was true for the demographic and general comor-
bidity variables. It is interesting to note that when
treatment was added as a covariate to the survival mod-
els, the results pertaining to black race were consistent
with those in the base case analyses, except that the
coefficients were smaller in the models that included
treatment. This suggests that poorer access to treatment
partially, but not fully, explains the disparities in survival
we observed.
While our findings suggest that racial differences in
all-cause mortality are due primarily to causes other
than NHL, it is important to interpret the findings in
the context of several limitations of our study. First, in
SEER, the cause of death is obtained from state death
certificates, and the underlying cause as coded by state
health departments is accepted [22]. There is no cause
of death listed on the Medicare side of SEER-Medicare,
and it is therefore acknowledged that cause of death is
inherently less reliable than other SEER variables [22].
In our study, 50% of patients who died from other/
unknown causes had no cause of death assigned. It is
possible that some of these patients died of causes
related to NHL. This might have artificially inflated the
actual association between black race and other/
unknown cause mortality. We are not aware of any
Table 3 Multivariate Survival Analysis (Continued)
Percent living in poverty in census tract
0-< 5% ref.
5-< 7% 1.04 0.49 0.94 1.15 1.11 0.13 0.97 1.26 0.96 0.57 0.82 1.12
7-< 12% 1.03 0.58 0.94 1.12 1.01 0.83 0.90 1.14 1.05 0.51 0.92 1.20
≥12% 1.13 0.01 1.03 1.23 1.11 0.09 0.99 1.25 1.17 0.03 1.02 1.33
SEER region
CA ref.
CT 1.08 0.29 0.94 1.25 1.08 0.42 0.89 1.31 1.09 0.45 0.88 1.34
Detroit 1.12 0.10 0.98 1.27 1.16 0.09 0.98 1.38 1.04 0.72 0.85 1.27
HI 0.81 0.16 0.60 1.09 0.66 0.07 0.42 1.03 0.98 0.90 0.65 1.47
IA 0.98 0.81 0.86 1.12 1.08 0.36 0.91 1.28 0.85 0.13 0.70 1.05
NM 1.24 0.04 1.01 1.52 1.32 0.05 1.00 1.74 1.15 0.38 0.84 1.58
Seattle 1.02 0.82 0.88 1.17 1.15 0.12 0.96 1.38 0.82 0.09 0.64 1.03
UT 1.01 0.88 0.85 1.21 1.15 0.24 0.91 1.44 0.84 0.25 0.63 1.13
Atlanta 0.96 0.71 0.78 1.18 0.98 0.86 0.74 1.28 0.97 0.85 0.72 1.32
Rural GA 0.97 0.91 0.55 1.72 0.90 0.79 0.40 2.02 1.01 0.99 0.45 2.27
KY 1.12 0.07 0.99 1.26 1.16 0.07 0.99 1.36 1.06 0.52 0.89 1.27
LA 1.07 0.34 0.93 1.22 1.13 0.16 0.95 1.35 0.97 0.80 0.80 1.19
NJ 1.12 0.03 1.01 1.25 1.11 0.15 0.96 1.27 1.16 0.06 1.00 1.35
Lymph node site
Nodal ref.
Extranodal 1.09 0.05 1.00 1.18 1.06 0.33 0.94 1.19 1.13 0.05 1.00 1.28
Other conditions
Anemia 1.31 <
0.0001
1.19 1.45 1.37 <
0.0001
1.20 1.55 1.23 0.01 1.05 1.43
Neutropenia 1.03 0.93 0.55 1.93 0.80 0.67 0.30 2.17 1.35 0.48 0.59 3.08
Thrombocytopenia 1.03 0.86 0.73 1.46 0.98 0.91 0.62 1.54 1.17 0.57 0.68 2.00
Cardiovascular
disease
1.26 <
0.0001
1.14 1.39 1.09 0.21 0.95 1.26 1.53 <
0.0001
1.31 1.77
HR: Hazard Ratio
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Page 10 of 14Table 4 Multivariate Survival Analysis - All-Cause Mortality, by Stage
Stage I-II Stage III-IV
HR p-value 95% CI HR p-value 95% CI
Age
66-< 70 ref ref
70-< 75 1.40 < 0.001 1.16 1.70 1.32 < 0.01 1.12 1.55
75-< 80 1.72 < 0.0001 1.43 2.07 1.74 < 0.0001 1.48 2.04
≥ 80 2.90 < 0.0001 2.44 3.45 2.45 < 0.0001 2.11 2.85
Gender
Female ref.
Male 1.12 0.02 1.02 1.23 1.06 0.17 0.97 1.16
Race
White ref.
Black 1.16 0.24 0.91 1.49 1.35 0.01 1.08 1.69
Other 0.99 0.93 0.83 1.19 1.20 0.04 1.01 1.42
DLBCL histology
9680 ref.
9684 1.45 0.02 1.07 1.96 1.39 0.02 1.06 1.83
Stage at diagnosis
I ref. N/A
II 1.29 < 0.0001 1.17 1.41 N/A
III N/A ref.
IV N/A 1.38 < 0.001 1.16 1.66
NCI Comorbidity Index
0 ref.
1 1.23 < 0.001 1.10 1.38 1.13 0.03 1.01 1.26
2 1.47 < 0.0001 1.25 1.73 1.38 < 0.0001 1.18 1.61
≥3 1.99 < 0.0001 1.65 2.39 1.73 < 0.0001 1.44 2.08
Year of diagnosis
2001 ref.
2002 0.94 0.40 0.82 1.08 0.80 < 0.01 0.70 0.91
2003 0.86 0.04 0.75 1.00 0.78 < 0.001 0.68 0.89
2004 0.88 0.10 0.76 1.02 0.77 < 0.001 0.67 0.88
2005 0.88 0.09 0.75 1.02 0.75 < 0.0001 0.65 0.86
Percent of 25+ year olds in census tract with some college
0-< 25% ref.
25-< 50% 1.04 0.47 0.93 1.16 0.97 0.56 0.87 1.08
≥50% 0.54 0.09 0.26 1.09 1.28 0.45 0.68 2.42
Percent living in poverty in census tract
0-< 5% ref.
5-< 7% 1.06 0.43 0.92 1.23 1.02 0.78 0.88 1.18
7-< 12% 1.00 1.00 0.87 1.14 1.09 0.18 0.96 1.24
≥12% 1.21 < 0.01 1.06 1.39 1.12 0.09 0.98 1.27
SEER region
CA ref.
CT 1.16 0.15 0.95 1.42 1.04 0.75 0.84 1.28
Detroit 1.10 0.35 0.90 1.33 1.19 0.07 0.99 1.43
HI 0.71 0.13 0.46 1.11 0.87 0.53 0.57 1.34
IA 0.91 0.38 0.75 1.12 1.01 0.95 0.84 1.21
NM 1.09 0.61 0.79 1.49 1.27 0.13 0.93 1.73
Seattle 0.98 0.87 0.78 1.23 1.03 0.75 0.85 1.25
UT 1.04 0.75 0.81 1.34 1.01 0.94 0.78 1.31
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Page 11 of 14studies that validate the cause of death as recorded in
SEER for patients with NHL. However, a recent study
showed that cause of death coding for colon cancer in
SEER had an estimated validity of 94.6% [31]. Of note,
the estimated validity was lower for blacks (84.4%) com-
pared to whites (95.4%), suggesting that any misclassifi-
cation in our study could have impacted black patients
disproportionately. If fewer blacks than whites were cor-
rectly assigned NHL as the cause of death, this could
have artificially deflated the actual association between
black race and NHL mortality in our analysis.
Second, observed disparities in cancer outcomes
among racial and ethnic minorities can reflect obstacles
to receiving health care services, including prevention,
early detection, and high quality treatment [1]. Although
one overriding factor is poverty [1], disparities have
been shown to exist even when access-related factors
such as insurance status and the ability to pay for care
are the same across racial and ethnic groups [11]. Our
study was conducted in a cohort of SEER-Medicare
patients who had Medicare Part A and Part B insurance
for at least one year before DLBCL diagnosis and
throughout the observation period following diagnosis.
Furthermore, we included measures of income and edu-
cation in our multivariate treatment and survival mod-
els. Patient selection and the inclusion of income and
education variables should have reduced the impact of
insurance status and ability to pay as access-related fac-
tors in our analyses. However, we were unable to
account for potential differences in Part B and Part D
supplemental insurance (to cover Part B copayments) in
our analyses. Also, we were unable to account for dispa-
rities in health insurance prior to Medicare eligibility,
which could have affected access to health services,
comorbidity, and severity of DLBCL at diagnosis in ways
we could not adjust for in our analyses. Moreover, since
SEER-Medicare does not report income and education
levels for individual patients, we relied on census tract-
level data.
Third, our study was based on the same data set used
by Wang and colleagues in their earlier study [14], and
our approaches were similar. Although both studies
showed racial disparities in treatment, only ours also
showed a difference in mortality. However, since we did
not have access to SEER-Medicare data for the earlier
time period in which Wang and colleagues conducted
their study, we cannot conclude that the racial dispari-
ties in mortality we observed indicate a fundamental
change from the earlier period. Rather, it could reflect
differences in the patient population or analytic
approach between our study and that of Wang and col-
leagues [14].
Finally, our study included a cohort of very elderly
patients, with a median age of 77 years. As shown, mor-
tality was high in this population, with only 50% surviv-
ing beyond two years. As a result, our findings may not
be applicable to younger patients who have a lower risk
of mortality overall. Certainly, studies of current treat-
ment modalities for DLBCL would suggest survival is
considerably better in younger patients [6].
Conclusions
Our findings show that the treatment rate was lower
and the mortality rate was higher in black compared to
white patients diagnosed with DLBCL. It is likely that
the observed differences in mortality between blacks and
whites are due to a number of factors, including differ-
ences in cancer and non-cancer related morbidity, as
well as differences in treatment.
Appendix
Table 4 Multivariate Survival Analysis - All-Cause Mortality, by Stage (Continued)
Atlanta 1.28 0.12 0.94 1.74 0.82 0.19 0.62 1.10
Rural GA 0.93 0.86 0.41 2.10 1.09 0.87 0.40 2.96
KY 1.01 0.91 0.84 1.21 1.27 0.01 1.06 1.51
LA 1.05 0.65 0.86 1.27 1.06 0.54 0.88 1.29
NJ 1.26 < 0.01 1.08 1.47 1.04 0.60 0.90 1.21
Lymph node site
Nodal ref.
Extranodal 1.13 0.01 1.03 1.24 0.94 0.52 0.77 1.14
Other conditions
Anemia 1.37 < 0.0001 1.18 1.60 1.25 < 0.01 1.08 1.44
Neutropenia 1.53 0.35 0.62 3.77 0.59 0.37 0.19 1.87
Thrombocytopenia 1.23 0.49 0.69 2.19 0.96 0.87 0.61 1.53
Cardiovascular disease 1.33 < 0.001 1.14 1.54 1.18 0.04 1.01 1.37
HR: Hazard Ratio
N/A: Not Applicable
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